2014
Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report
Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report. British Journal Of Radiology 2014, 87: 20140307. PMID: 25230161, PMCID: PMC4170864, DOI: 10.1259/bjr.20140307.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsAdverse drug eventsDrug eventsMedicines AgencyGadopentetate dimeglumineDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemDanish Medicines AgencyNephrogenic systemic fibrosisEvent Reporting SystemEuropean Medicines AgencyNSF casesHistopathological dataContrast agentsSystemic fibrosisDrug AdministrationLegal data setsUnconfounded casesGadobenate dimeglumineMean numberDimeglumineReporting systemPharmacovigilance researchSafety informationPharmacovigilance
2005
Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing Dermopathy
Cowper SE. Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing Dermopathy. American Journal Of Kidney Diseases 2005, 46: 763-765. PMID: 16183434, DOI: 10.1053/j.ajkd.2005.08.008.Commentaries, Editorials and LettersCase 35-2004: nephrogenic fibrosing dermopathy.
Cowper S, Bucala R, LeBoit P. Case 35-2004: nephrogenic fibrosing dermopathy. New England Journal Of Medicine 2005, 352: 1723-4; author reply 1723-4. PMID: 15846862.Peer-Reviewed Original Research